Chemokines as therapeutic targets for atherosclerotic plaque destabilization and rupture

Future Cardiology

Volumn 5, Issue 3, 2009, Pages 273-284

  Daissormont, Isabelle T M N ^a   Kraaijeveld, Adriaan O ^b   Biessen, Erik A L ^a  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b LEIDEN UNIVERSITY   (Netherlands)

Author keywords

Atherosclerosis; Chemokines; Plaque rupture; Therapy

Indexed keywords

4 [(4 BROMOPHENYL)(ETHOXYIMINO)METHYL] 1' [(2,4 DIMETHYL 3 PYRIDINYL)CARBONYL] 4' METHYL 1,4' BIPIPERIDINE; CCL1 CHEMOKINE; CCL18 CHEMOKINE; CHEMOKINE; CHEMOKINE RECEPTOR ANTAGONIST; CHEMOKINE RECEPTOR CCR2; CHEMOKINE RECEPTOR CCR2 ANTAGONIST; CHEMOKINE RECEPTOR CXCR3; CHEMOKINE RECEPTOR CXCR4; CHEMOKINE RECEPTOR CXCR4 ANTAGONIST; FRACTALKINE; GAMMA INTERFERON INDUCIBLE PROTEIN 10; JNJ 27141491; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MLN 1202; MONOCYTE CHEMOTACTIC PROTEIN 1; MONOCYTE CHEMOTACTIC PROTEIN 1 ALPHA; N [4 [[[6,7 DIHYDRO 2 (4 METHYLPHENYL) 5H BENZOCYCLOHEPTEN 8 YL]CARBONYL]AMINO]BENZYL] N,N DIMETHYL 2H TETRAHYDROPYRAN 4 AMINIUM CHLORIDE; RANTES; STROMAL CELL DERIVED FACTOR 1; THROMBOCYTE FACTOR 4; UNCLASSIFIED DRUG; VICRIVIROC; BIOLOGICAL MARKER; CCL2 PROTEIN, HUMAN;

ANTIINFLAMMATORY ACTIVITY; ATHEROGENESIS; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; ATHEROSCLEROTIC PLAQUE RUPTURE; CELL MIGRATION; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CORONARY ARTERY DISEASE; CYTOKINE RELEASE; DISEASE MODEL; DRUG TARGETING; ENDOTHELIUM CELL; GENE EXPRESSION; HEART INFARCTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFLAMMATORY CELL; LEUKOCYTE FUNCTION; MACROPHAGE; MONOCYTE; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN FUNCTION; PSORIASIS; REVIEW; RHEUMATOID ARTHRITIS; THROMBOEMBOLISM; VASCULAR ENDOTHELIUM; ANIMAL; BLOOD; DISEASE COURSE; DRUG EFFECTS; INFLAMMATION; MOUSE; PATHOLOGY; PHYSIOLOGY; RUPTURE;

ANIMALS; ATHEROSCLEROSIS; BIOLOGICAL MARKERS; CHEMOKINE CCL2; CHEMOKINES; CORONARY ARTERY DISEASE; DISEASE PROGRESSION; HUMANS; INFLAMMATION; MICE; RUPTURE, SPONTANEOUS;

EID: 67049086576     PISSN: 14796678     EISSN: 17448298     Source Type: Journal    
DOI: 10.2217/fca.09.4     Document Type: Review

References (83)

1. Ross R: Atherosclerosis - an inflammatory disease. N. Engl. J. Med. 340(2), 115-126 (1999).
2. Libby P, Ridker PM, Maseri A: Inflammation and atherosclerosis. Circulation 105(9), 1135-1143 (2002).
3. Felton CV, Crook D, Davies MJ, Oliver MF: Relation of plaque lipid composition and morphology to the stability of human aortic plaques. Arterioscler. Thromb. Vasc. Biol. 17(7), 1337-1345 (1997).
4. Davies MJ, Richardson PD, Woolf N, Katz DR, Mann J: Risk of thrombosis in human atherosclerotic plaques: role of extracellular lipid, macrophage, and smooth muscle cell content. Br. Heart J. 69(5), 377-391 (1993).
5. Leroyer AS, Tedgui A, Boulanger CM: Role of microparticles in atherothrombosis. J. Intern. Med. 263(5), 528-537 (2008).
6. Bennett MR, Evan GI, Schwartz SM: Apoptosis of human vascular smooth muscle cells derived from normal vessels and coronary atherosclerotic plaques. J. Clin. Invest. 95(5), 2266-2274 (1995).
7. Lutgens E, de Muinck ED, Kitslaar PJ et al.: Biphasic pattern of cell turnover characterizes the progression from fatty streaks to ruptured human atherosclerotic plaques. Cardiovasc. Res. 41(2), 473-479 (1999).
8. Clarke MC, Figg N, Maguire JJ et al.: Apoptosis of vascular smooth muscle cells induces features of plaque vulnerability in atherosclerosis. Nat. Med. 12(9), 1075-1080 (2006).
9. Yilmaz A, Lipfert B, Cicha I et al.: Accumulation of immune cells and high expression of chemokines/chemokine receptors in the upstream shoulder of atherosclerotic carotid plaques. Exp. Mol. Pathol. 82(3), 245-255 (2007).
10. Takaya N, Yuan C, Chu B et al.: Presence of intraplaque hemorrhage stimulates progression of carotid atherosclerotic plaques: a high-resolution magnetic resonance imaging study. Circulation 111(21), 2768-2775 (2005).
11. de Boer OJ, van der Wal AC, Teeling P, Becker AE: Leucocyte recruitment in rupture prone regions of lipid-rich plaques: a prominent role for neovascularization? Cardiovasc. Res. 41(2), 443-449 (1999).
12. Farb A, Burke AP, Tang AL et al.: Coronary plaque erosion without rupture into a lipid core. A frequent cause of coronary thrombosis in sudden coronary death. Circulation 93(7), 1354-1363 (1996).
13. Martinovic I, Abegunewardene N, Seul M et al.: Elevated monocyte chemoattractant protein-1 serum levels in patients at risk for coronary artery disease. Circ. J. 69(12), 1484-1489 (2005).
14. Arkelyan A, Petrkova J, Hermanova Z et al.: Serum levels of the MCP-1 chemokine in patients with ischemic stroke and myocardial infarction. Mediators Inflamm. 2005(3), 175-179 (2005).
15. de Lemos JA, Morrow DA, Sabatine MS et al.: Association between plasma levels of monocyte chemoattractant protein-1 and long-term clinical outcomes in patients with acute coronary syndromes. Circulation 107(5), 690-695 (2003).
16. Herder C, Baumert J, Thorand B et al.: Chemokines and incident coronary heart disease: results from the MONICA/KORA Augsburg case-cohort study, 1984-2002. Arterioscler. Thromb. Vasc. Biol. 26(9), 2147-2152 (2006).
17. Kraaijeveld AO, de Jager SC, de Jager WJ et al.: CC chemokine ligand-5 (CCL5/RANTES) and CC chemokine ligand-18 (CCL18/PARC) are specific markets of refractory unstable angina pectoris and are transiently raised during severe ischemic symptoms. Circulation 116(17), 1931-1941 (2007).
18. Gonzalez P, Alvarez R, Batalla A et al.: Generic variation at the chemokine receptors CCR5/CCR2 in myocardial infarction. Genes Immun. 2(4), 191-195 (2001).
19. de Jager SC, Kraaijeveld AO, Grauss RW et al.: CCL3 (MIP-1 α) levels are elevated during acute coronary syndromes and show strong prognostic power for future ischemic events. J. Mol. Cell Cardiol. 45(3), 446-452 (2008).
20. Damas JK, Waehre T, Yndestad A et al.: Stromal cell-derived factor-1α in unstable angina: potential antinflammatory and matrix-stabilizing effects. Circulation 106(1), 36-42 (2002).
21. Abi-Younes S, Sauty A, Mach F et al.: The stromal cell-derived factor-1 chemokine is a potent platelet agonist highly expressed in atherosclerotic plaques. Circ. Res. 86(2), 131-138 (2000).
22. Damas JK, Boullier A, Waehre T et al.: Expression of fractalkine (CX3CL1) and its receptor, CX3CR1, is elevated in coronary artery disease and is reduced during statin therapy. Arterioscler Thromb. Vasc. Biol. 25(12), 2567-2572 (2005).
23. McDermott DH, Fong AM, Yang Q et al.: Chemokine receptor mutant CX3CR1-M280 has impaired adhesive function and correlates with protection from cardiovascular disease in humans. J. Clin. Invest. 111(8), 1241-1250 (2003).
24. Papaspyridonos M, Smith A, Burnand KG et al.: Novel candidate genes in unstable areas of human atherosclerotic plaques. Arterioscler. Thromb. Vasc. Biol. 26(8), 1837-1844 (2006).
25. Randi AM, Biguzzi E, Falciani F et al.: Identification of differentially expressed genes in coronaty atherosclerotic plaques from patients with stable or unstable angina by cDNA array analysis. J. Thromb. Haemost. 1(4), 829-835 (2003).
26. Lutgens E, Faber B, Schapira K et al.: Gene profiling in atherosclerosis reveals a key role for small inducible cytokines: validation using a novel monocyte chemoattractant protein monoclonal antibody. Circulation 111(25), 3443-3452 (2005).
27. Carr MW, Roth SJ, Luther E, Rose SS, Springer TA: Monocyte chemoattractant protein 1 acts as a T-lymphocyte chemoattractant. Proc. Natl Acad. Sci. USA 91(9), 3652-3656 (1994).
28. Xu LL, Warren MK, Rose WL, Gong W, Wang JM: Human recombinant monocyte chemotactic protein and other C-C chemokines bind and induce directional migration of dendritic cells in vitro. J. Leukoc. Biol. 60(3), 365-371 (1996).
29. Garcia-Zepeda EA, Combadiere C, Rothenberg ME et al.: Human monocyte chemoattractant protein (MCP)-4 is a novel CC chemokine with activities on monocytes, eosinophils, and basophils induced in allergic and nonallergic inflammation that signals through the CC chemokine receptors (CCR) -2 and -3. J. Immunol. 157(12), 5613-5626 (1996).
30. Yla-Herttuala S, Lipton BA, Rosenfeld ME et al.: Expression of monocyte chemoattractant protein 1 in macrophage-rich areas of human and rabbit atherosclerotic lesions. Proc. Natl Acad. Sci. USA 88(12), 5252-5256 (1991).
31. Yu X, Dluz S, Graves DT et al.: Elevated expression of monocyte chemoattractant protein 1 by vascular smooth muscle cells in hypercholesterolemic primates. Proc. Natl Acad. Sci. USA 89(15), 6953-6957 (1992).
32. Takahashi M, Masuyama J, Ikeda U et al.: Induction of monocyte chemoattractant protein-1 synthesis in human monocytes during transendothelial migration in vitro. Circ. Res. 76(5), 750-757 (1995).
33. Papadopoulou C, Corrigall V, Taylor PR, Poston RN: The role of the chemokines MCP-1, GRO-α, IL-8 and their receptors in the adhesion of monocytic cells to human atherosclerotic plaques. Cytokine 43(2), 181-186 (2008).
34. Gawaz M, Neumann FJ, Dickfeld T et al.: Activated platelets induce monocyte chemotactic protein-1 seeretinin and surface expression of intercellular adhesion molecule-1 on endothelial cells. Circulation 98(12), 1164-1171 (1998).
35. Struyf S, De Meester I, Scharpe S et al.: Natural truncation of RANTES abolishes signaling through the CC chemokine receptors CCR1 and CCR3, impairs its chemotactic potency and generates a CC chemokine inhibitor. Eur. J. Immunol. 28(4), 1262-1271 (1998).
36. Vellard NR, Steffens S, Burger F, Pelli G, Mach F: Differential expression patterns of proinflammatory and antinflammatory mediators during atherogenesis in mice. Arterioscler. Thromb. Vasc. Biol. 24(12), 2339-2344 (2004).
37. Wilcox JN, Nelken NA, Coughlin SR, Gordon D, Schall TJ: Local expression of inflammatory cytokines in human atherosclerotic plaques. J. Atheroscler. Thromb. 1(Suppl. 1), S10-S13 (1994).
38. Haley KJ, Lilly CM, Yang JH et al.: Overexpression of eotaxin and the CCR3 receptor in human atherosclerosis: using genomic technology to identify a potential novel pathway of vascular inflammation. Circulation 102(18), 2185-2189 (2000).
39. Hagg DA, Olson FJ, Kjelldahl J et al.: Expression of chemokine (C-C motif) ligand 18 in human macrophages and atherosclerotic plaques. Atherosclerosis (2008).
40. Farber JM: Mig and IP-10: CXC chemokines that target lymphocytes. J. Leukoc. Biol. 61(3), 246-257 (1997).
41. Cheng C, Tempel D, van Haperen R et al.: Shear stress-induced changes in atherosclerotic plaque composition are modulated by chemokines. J. Clin. Invest. 117(3), 616-626 (2007).
42. Luster AD, Ravetch JV: Biochemical characterization of a γ interferon-inducible cytokine (IP-10). J. Exp. Med. 166(4), 1084-1097 (1987).
43. Martinez FO, Sica A, Mantovani A, Locati M: Macrophage activation and polarization. Front. Biosci. 13, 453-461 (2008).
44. Mach F, Sauty A, Iarossi AS et al.: Differential expression of three T lymphocyte-activating CXC chemokines by human atheroma-associated cells. J. Clin. Invest. 104(8), 1041-1050 (1999).
45. Valentin G, Haas P, Gilmour D: The chemokine SDF1a coordinates tissue migration through the spatially restricted activation of Cxcr7 and Cxcr4b. Curr. Biol. 17(12), 1026-1631 (2007).
46. Zernecke A, Bot I, Djalali-Talab Y et al.: Protective role of CXC receptor 4/CXC ligand 12 unveils the importance of neutrophils in atherosclerosis. Circ. Res. 102(2), 209-217 (2008).
47. Pitsilos S, Hunt J, Mohler ER et al.: Platelet factor 4 localization in carotid atherosclerotic plaques: correlation with clinical parameters. Thromb. Haemost. 90(6), 1112-1120 (2003).
48. Yu G, Rux AH, Ma P, Bdeir K, Sachais BS: Endothelial expression of E-selectin is induced by the platelet-specific chemokine platelet factor 4 through LRP in an NF-κB-dependent manner. Blood 105(9), 3545-3551 (2005).
49. Bazan JF, Bacon KB, Hardiman G et al.: A new class of membrane-bound chemokine with a CX3C motif. Nature 385(6617), 640-644 (1997).
50. Greaves DR, Hakkinen T, Lucas AD et al.: Linked chromosome 16q13 chemokines, macrophage-derived chemokine, fractalkine, and thymus- and activation-regulated chemokine, are expressed in human atherosclerotic lesions. Arterioscler. Thromb. Vasc. Biol. 21(6), 923-929 (2001).
51. Lucas AD, Bursill C, Guzik TJ et al.: Smooth muscle cells in human atherosclerotic plaques express the fractalkine receptor CX3CR1 and undergo chemotaxis to the CX3C chemokine fractalkine (CX3CL1). Circulation 108(20), 2498-2504 (2003).
52. -/- mice reveals a role for chemokines in the initiation of atherosclerosis. Nature 394(6696), 894-897 (1998).
53. Gu L, Okada Y, Clinton SK et al.: Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low density lipoprotein receptor-deficient mice. Mol. Cell 2(2), 275-281 (1998).
54. Inoue S, Egashira K, Ni W et al.: Anti-monocyte chemoattractant protein-1 gene therapy limits progression and destabilization of established atherosclerosis in apolipoprotein E-knockout mice. Circulation 106(21), 2700-2706 (2002).
55. Ni W, Kitamoto S, Ishibashi M et al.: Monocyte chemoattractant protein-1 is an essential inflammatory mediator in angiotensin II-induced progression of established atherosclerosis in hypercholesterolemic mice. Arterioscler. Thromb. Vasc. Biol. 24(3), 534-539 (2004).
56. Kuziel WA, Dawson TC, Quinones M et al.: CCR5 deficiency is not protective in the early stages of atherogenesis in apoE knockout mice. Atherosclerosis 167(1), 25-32 (2003).
57. Veillard NR, Kwak B, Pelli G et al.: Antagonism of RANTES receptors reduces atherosclerotic plaque formation in mice. Circ. Res. 94(2), 253-261 (2004).
58. Braunersrenther V, Steffens S, Arnaud C et al.: A novel RANTES antagonist prevents progression of established atherosclerotic lesions in mice. Arterioscler. Thromb. Vasc. Biol. 28(6), 1090-1096 (2008).
59. Potteaux S, Combadiere C, Esposito B et al.: Role of bone marrow-derived CC-chemokine receptor 5 in the development of atherosclerosis of low-density lipoprotein receptor knockout mice. Arterioscler. Thromb. Vasc. Biol. 26(8), 1858-1863 (2006).
60. Quinones MP, Martinez HG, Jimenez F et al.: CC chemokine receptor 5 influences late-stage atherosclerosis. Atherosclerosis 195(1), E92-E103 (2007).
61. Potteaux S, Combadiere C, Esposito B et al.: Chemokine receptor CCR1 disruption in bone marrow cells enhances atherosclerotic lesion development and inflammation in mice. Mol. Med. 11(1-12), 16-20 (2005).
62. Braunersreuther V, Zernecke A, Arnaud C et al.: Ccr5 but not Ccr1 deficiency reduces development of diet-induced atherosclerosis in mice. Arterioscler. Thromb. Vasc. Biol. 27(2), 373-379 (2007).
63. Heller EA, Liu E, Tager AM et al.: Chemokine CXCL10 promotes atherogenesis by modulating the local balance of effector and regulatory T cells. Circulation 113(19), 2301-2312 (2006).
64. van Wanrooij EJ, de Jager SC, van Es T et al.: CXCR3 antagonist NBI-74330 attenuates atherosclerotic plaque formation in LDL receptor-deficient mice. Arterioscler. Thromb. Vasc. Biol. 28(2), 251-257 (2008).
65. Veillard NR, Steffens S, Pelli G et al.: Differential influence of chemokine receptors CCR2 and CXCR3 in development of atherosclerosis in vivo. Circulation 112(6), 870-878 (2005).
66. King VL, Lin AY, Kristo F et al.: Interferon-γ and the interferon-inducible chemokine CXCL10 protect against aneurysm formation and rupture. Circulation 119(3), 426-435 (2009).
67. -/- mice. Thromb. Haemost. 98(5), 1108-1113 (2007).
68. Combadiere C, Potteaux S, Gao JL et al.: Decreased atherosclerotic lesion formation in CX3CR1/apolipoprotein E double knockout mice. Circulation 107(7), 1009-1016 (2003).
69. Vergunst CE, Gerlag DM, Lopatinskaya L et al.: Modulation of CCR2 in rheumatoid arthritis: a double-blind, randomized, placebo-controlled clinical trial. Arthritis Rheum. 58(7), 1931-1939 (2008).
70. Buntinx M, Hermans B, Goossens J et al.: Pharmacological profile of JNJ-27141491 [(S)-3-[3,4-difluorophenyl)-propyl]-5-isoxazol-5-yl-2- thioxo-2,3-dihydro-1 H-imidazole-4-carboxyl acid methyl ester], as a noncompetitive and orally active antagonist of the human chemokine receptor CCR2. J. Pharmacol. Exp. Ther. 327(1), 1-9 (2008).
71. van Wanrooij EJ, Happe H, Hauer AD et al.: HIV entry inhibitor TAK-779 attenuates atherogenesis in low-density lipoprotein receptor-deficient mice. Arterioscler. Thromb. Vasc. Biol. 25(12), 2642-2647 (2005).
72. Johnson Z, Kosco-Vilbois MH, Herren S et al.: Interference with heparin binding and oligomerization creates a novel anti-inflammatory strategy targeting the chemokine system. J. Immunol. 173(9), 5776-5785 (2004).
73. de Groot M, Teunissen MB, Ortonne JP, et al.: Expression of the chemokine receptor CCR5 in psoriasis and results of a randomized placebo controlled trial with a CCR5 inhibitor. Arch. Dermatol. Res. 299(7), 305-313 (2007).
74. Pugach P, Ketas TJ, Michael E, Moore JP: Neutralizing antibody and anti-retroviral drug sensitivities of HIV-1 isolates resistant to small molecule CCR5 inhibitors. Virology 377(2), 401-407 (2008).
75. Hendrix CW, Collier AC, Lederman MM et al.: Safety, pharmacokinetics, and antiviral activity of AMD3100, a selective. CXCR4 receptor inhibitor, in HIV-1 infection. J. Acquir. Immune Defic. Syndr. 37(2), 1253-1262 (2004).
76. Koenen RR, von Hundelshausen P, Nesmelova IV et al.: Disrupting functional interactions between platelet chemokines inhibits atherosclerosis in hyperlipidemic mice. Nat. Med. 15(1), 97-103 (2009).
77. Nanki T, Urasaki Y, Imai T et al.: Inhibition of fractalkine ameliorates murine collagen-induced arthritis. J. Immunol. 173(11), 7010-7016 (2004).
78. Zeng Y, Jiang J, Huebener N et al.: Fractalkine gene therapy for neuroblastoma is more effective in combination with targeted IL-2. Cancer Lett. 228(1-2), 187-193 (2005).
79. Rosenfeld ME, Polinsky P, Virmani R et al.: Advanced atherosclerotic lesions in the innominate artery of the ApoE knockout mouse. Arterioscler. Thromb. Vasc. Biol. 20(12), 2587-2592 (2000).
80. Johnson JL, Jackson CL: Atherosclerotic plaque rupture in the apolipoprotein E knockout mouse. Atherosclerosis 154(2), 399-406 (2001).
81. Calara F, Silvestre M, Casanada F et al.: Spontaneous plaque rupture and secondary thrombosis in apolipoprotein E-deficient and LDL receptor-deficient mice. J. Pathol. 195(2), 257-263 (2001).
82. Soriano V, Geretti AM, Perno CF et al.: Optimal use of maraviroc in clinical practice. AIDS 22(17), 2231-2240 (2008).
83. Stiff P, Micallef I, McCarthy P et al.: Treatment with plerixafor in non-Hodgkin's lymphoma and multiple myeloma patients to increase the number of peripheral blood stem cells when given a mobilizing regimen of G-CSF: implications for the heavily pretreated patient. Biol. Blood Marrow Transplant. 15(2), 249-256 (2009).